131 related articles for article (PubMed ID: 34294813)
1. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer.
Duan K; Jang GH; Grant RC; Wilson JM; Notta F; O'Kane GM; Knox JJ; Gallinger S; Fischer S
Sci Rep; 2021 Jul; 11(1):14951. PubMed ID: 34294813
[TBL] [Abstract][Full Text] [Related]
2. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.
O'Kane GM; Grünwald BT; Jang GH; Masoomian M; Picardo S; Grant RC; Denroche RE; Zhang A; Wang Y; Lam B; Krzyzanowski PM; Lungu IM; Bartlett JMS; Peralta M; Vyas F; Khokha R; Biagi J; Chadwick D; Ramotar S; Hutchinson S; Dodd A; Wilson JM; Notta F; Zogopoulos G; Gallinger S; Knox JJ; Fischer SE
Clin Cancer Res; 2020 Sep; 26(18):4901-4910. PubMed ID: 32156747
[TBL] [Abstract][Full Text] [Related]
3. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.
Eyres M; Lanfredini S; Xu H; Burns A; Blake A; Willenbrock F; Goldin R; Hughes D; Hughes S; Thapa A; Vavoulis D; Hubert A; D'Costa Z; Sabbagh A; Abraham AG; Blancher C; Jones S; Verrill C; Silva M; Soonawalla Z; Maughan T; Schuh A; Mukherjee S; O'Neill E
Gastroenterology; 2021 Aug; 161(2):653-668.e16. PubMed ID: 33915173
[TBL] [Abstract][Full Text] [Related]
4. GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery.
van Eijck CWF; Real FX; Malats N; Vadgama D; van den Bosch TPP; Doukas M; van Eijck CHJ; Mustafa DAM;
Cell Rep Med; 2024 May; 5(5):101557. PubMed ID: 38733987
[TBL] [Abstract][Full Text] [Related]
5. The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.
Martinelli P; Madriles F; Cañamero M; Pau EC; Pozo ND; Guerra C; Real FX
Gut; 2016 Mar; 65(3):476-86. PubMed ID: 25596178
[TBL] [Abstract][Full Text] [Related]
6. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
7. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer.
Martinelli P; Carrillo-de Santa Pau E; Cox T; Sainz B; Dusetti N; Greenhalf W; Rinaldi L; Costello E; Ghaneh P; Malats N; Büchler M; Pajic M; Biankin AV; Iovanna J; Neoptolemos J; Real FX
Gut; 2017 Sep; 66(9):1665-1676. PubMed ID: 27325420
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma.
Stubbe BE; Madsen PH; Larsen AC; Krarup HB; Pedersen IS; Hansen CP; Johansen JS; Henriksen SD; Thorlacius-Ussing O
Pancreatology; 2023 Aug; 23(5):512-521. PubMed ID: 37230892
[TBL] [Abstract][Full Text] [Related]
9. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of
Patil S; Steuber B; Kopp W; Kari V; Urbach L; Wang X; Küffer S; Bohnenberger H; Spyropoulou D; Zhang Z; Versemann L; Bösherz MS; Brunner M; Gaedcke J; Ströbel P; Zhang JS; Neesse A; Ellenrieder V; Singh SK; Johnsen SA; Hessmann E
Cancer Res; 2020 Nov; 80(21):4620-4632. PubMed ID: 32907838
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W
Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303
[No Abstract] [Full Text] [Related]
11. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
Meijer LL; Garajová I; Caparello C; Le Large TYS; Frampton AE; Vasile E; Funel N; Kazemier G; Giovannetti E
Ann Surg; 2020 Jun; 271(6):1137-1147. PubMed ID: 30394883
[TBL] [Abstract][Full Text] [Related]
12. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment.
Vuijk FA; de Muynck LDAN; Franken LC; Busch OR; Wilmink JW; Besselink MG; Bonsing BA; Bhairosingh SS; Kuppen PJK; Mieog JSD; Sier CFM; Vahrmeijer AL; Verheij J; Fariňa-Sarasqueta A; Swijnenburg RJ
Sci Rep; 2020 Oct; 10(1):16211. PubMed ID: 33004930
[TBL] [Abstract][Full Text] [Related]
13. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma.
Zhang SR; Li H; Wang WQ; Jin W; Xu JZ; Xu HX; Wu CT; Gao HL; Li S; Li TJ; Zhang WH; Xu SS; Ni QX; Yu XJ; Liu L
Eur J Surg Oncol; 2019 May; 45(5):769-775. PubMed ID: 30416079
[TBL] [Abstract][Full Text] [Related]
14. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
16. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
[TBL] [Abstract][Full Text] [Related]
17. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
18. GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1.
Zhong Y; Wang Z; Fu B; Pan F; Yachida S; Dhara M; Albesiano E; Li L; Naito Y; Vilardell F; Cummings C; Martinelli P; Li A; Yonescu R; Ma Q; Griffin CA; Real FX; Iacobuzio-Donahue CA
PLoS One; 2011; 6(7):e22129. PubMed ID: 21811562
[TBL] [Abstract][Full Text] [Related]
19. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
20. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
[Next] [New Search]